THE treatment of chronic lymphatic leukaemia has been assessed during the past ten years. External radiation therapy, radioisotopes such as 321p and chemotherapy have proved to be effective in the management of this disease (Dameshek and Gunz, 1964; Karnofsky, 1966; La Due and Molander, 1964; Wintrobe, 1961) . With the adequate administration of radiotherapy, chlorambucil and prednisone, patients with chronic lymphatic leukaemia can be maintained in fairly good clinical conditions for long periods of time, although whether the results of treatment can affect survivals is still debatable.
There have been no new drugs or new methods of treatment for chronic lymphatic leukaemia in the past few years (Dameshek and Gunz, 1964; Karnofsky, 1966; La Due and Molander, 1964; Wintrobe, 1961) . In our Institutes we have conducted experiments since 1961 into the therapeutic effects of a radioactive contrast medium (Lipiodol F 1311) introduced into the lymphatics of the dorsum of the foot in more than 200 cases of retroperitoneal malignant lymphomas (Buraggi, D'Amico and Fava, 1963; Chiappa, 1963; Chiappa, Galli and Palmia, 1964; Chiappa et al., 1965; Chiappa, Galli and Severini, 1964) as well as in several patients with carcinomas metastatic to the retroperitoneal nodes (Chiappa et al., 1966; Chiappa et al., 1963) .
Such a wide experience has proved that the administration of Lipiodol F 131I provides a good palliative treatment with a remarkable and long-standing shrinkage of all adequately opaque nodes without producing untoward effects (Bagliani, Chiappa and Galli, 1964) . This treatment has been called by us endolymphatic radiotherapy.
The present report is a preliminary one and deals with a group of 17 patients with chronic lymphatic leukaemia in which Lipiodol F 1311 has been injected into the lymph channels of the dorsum of the foot in order to see whether a good control of the retroperitoneal adenopathies could be achieved also in this disease.
MATERIALS AND METHODS
Seventeen patients with chronic lymphatic leukaemia have been studied. The morphological diagnosis was made through bone marrow aspirates and peripheral blood smears. The patients were classified into 4 groups according to the four types proposed by Dameshek and Gunz (1964 Lipiodol F 131J was injected into the lymphatics of the dorsum of the foot following the technique proposed by Kinmonth (Kinmonth, Taylor and Herper, 1955) . The doses per foot ranged from 0*7 to 2-5 mc/c.c., as can be seen from Table I . Three patients (Cases No. 4, 11, 15) received two injections of Lipiodol F 131I, one because of relapse (Case 4) and two because the retroperitoneal nodes were too large to be filled adequately with the standard dose of 10 c.c. of radioactive contrast medium in each lower limb. Two patients (Cases No. 7, 8) were injected only in one lower limb because a good lymph vessel was not found in the opposite side. One patient (Case No. 9) received normal Lipiodol F in one foot and Lipiodol F 131J in the opposite one.
RESULTS
The most important findings are summarized in Table I . Three cases (No. 7, 13, 17) have been classified as Type I patients. All the other fourteen cases belong 
*: the second dose was injected 3 years after the first. ** the second dose was injected 15 days after the first.
: the second dose was injected 7 days after the first. 0: Lipiodol F 131J injected only in the right foot.
to Type II and only one patient (Case No. 12) was proved to have an haemolytic anaemia (positive Coomb's test). Extensive retroperitoneal node involvement was found in practically all patients with the classic form of chronic lymphatic leukaemia. A good lymph node shrinkage was observed in all treated patients (Fig. 1, 2, 3 , 4, 5) even in cases 2, 3 and 4 who received low doses of Lipiodol F 1311 (0.7-0-8 mc/c.c.). The initial node regression was already present before the end of the second week (Fig. 2, 5 ). The lymph node shrinkage was observed with monthly follow-up films until Lipiodol F 131J was completely reabsorbed (about 6-10 months). In one case (Fig. 1 ) the contrast medium remained in the lymph nodes two years. This allowed us to detect a relapse in the external iliac chains. In one patient (Case No. 4) because of inadequate filling of the left para-aortic and inguinal nodal masses, external radiation therapy with Cobalt was used. Two patients (Cases 2 and 3) died, outside the hospital, 1 month after the administration of endolymphatic radiotherapy. The exact clinical cause of death is unknown. In all other patients no complications or untoward effects due to Lipiodol F 131I were observed (pulmonary or hepatic insufficiency) nor were haemolytic anaemias detected.
DISCUSSION
It is well-known that chronic lymphatic leukaemia is a neoplastic disease which belongs to the group of lymphoproliferative disorders (Dameshek and Gunz, 1964) . Its cause remains still unknown, and the disease, which is self-perpetuating, The treatment of choice will depend on the patient's clinical condition and the physician's facilities and experience. Treatment is not indicated for the benign form (Type I) unless symptoms arise or the leukocyte count reaches very high levels. On the contrary therapy is necessary in the typical " aggressive " variety (Type II) which in the majority of cases is a symptom-producing disease. In these cases external radiation therapy is given to bulky nodes wherever the location, or to the enlarged spleen. Alkylating agents (TEM, chlorambucil, cyclophosphamide) are often given in combination (Dameshek and Gunz, 1964; Karnofsky, 1966; La Due and Molander, 1964; Wintrobe, 1961) , and usually administered in a cautious schedule to avoid excessive destruction of lymphoid tissue or severe bone marrow depression which can result in serious complications more disabling than the disease itself (Diamond and Miller, 1961) .
As can be seen from our limited case material, retroperitoneal node involvement is very frequent in Type II of chronic lymphatic leukaemia (14/17 cases). All 3 Type I patients had mild retroperitoneal adenopathy. The large nodal masses which are often symptomatic (constipation, diarrhoea, back pain) require therapy and specifically radiation therapy to produce a fairly rapid and adequate shrinkage of the bulky nodes. Our experience achieved with the treatment of similar clinical situations in malignant lymphomas suggested the choice of Lipiodol F 1311 over cobalt-teletherapy for the inguinal and the retroperitoneal node involvement (Chiappa, Galli and Severini, 1964) . The reasons for this preference are due to the fact that endolymphatic radiotherapy can be administered in one single injection and does not produce any radiation sickness effects which often occur when multiple large ports are employed over the abdomen. Endolymphatic radiotherapy has been administered in combination with polyfunctional alkylating agents (TEM, chlorambucil) and corticosteroids (prednisone) to control all sites of the disease. The promising clinical results obtained by these therapeutic associations (Table I) warrant further trials with larger numbers of patients, especially in order to determine the length of regression.
A few other authors in Europe (Jantet, 1962; Picard et al., 1964) and in the U.S.A. (Ariel, 1963; Liebner, 1965; Seitzman et al., 1963; Seitzman et al., 1964) have recently used endolymphatic radiotherapy for the palliative treatment of retroperitoneal metastases of malignant lymphomas and carcinomas. We are not aware of any therapeutic trial undertaken in chronic lymphatic leukaemia.
In conclusion we recommend endolymphatic radiotherapy in the treatment of inguinal and retroperitoneal node involvement in Type II of chronic lymphatic leukaemia. This method of treatment seems to be effective without doing any harm to the patients which are not exposed to the side effects of radiation therapy when high voltage machines and large ports are used. We do not advise endolymphatic radiotherapy in Type I patients to avoid excessive destruction of probably normal lymphoid tissue and the possible triggering of a haemolytic anaemia (Dameshek and Gunz, 1964) 
